Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) shares hit a new 52-week high on Monday . Jefferies Financial Group started coverage on Stoke Therapeutics in a research report on Friday, July 18th. Also, Director Edward M. Md Kaye sold 45,996 shares of Stoke Therapeutics stock in a transaction dated Wednesday, September 3rd. Stoke Therapeutics Company Profile(Get Free Report)Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. Featured StoriesReceive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.